'A tax on being thin': only high earners make overall savings on food bills from weight-loss drugs
Guardian AU Business
β’Sat, 15 Aug 2026 07:00:50 GMT
π° What Happened
Weight-loss medication is being called a tax on being thin. An analysis by consultancy Baringa says the high cost outweighs any saving on food for most people. Someone needs discretionary income of nearly Β£100,000 a year to actually save money. The annual cost of the medication averages Β£1,200. Baringa said GLP-1s risk becoming a driver of inequality. Only very high earners will benefit.
π The Backstory
Nearly three million people in Britain are on weight-loss medication. Most buy the drugs privately with a prescription. A GLP-1 user with Β£39,000 left after tax and essentials spends Β£481 less a year on food. But people do not save the full Β£1,200 on groceries until they have Β£97,500 left after tax. A regressive tax takes a larger share from lower-wage earners. Baringa notes the outlay is an average for the pill form of the drug.
π― Why It Matters
The cost of these drugs could widen the gap between rich and poor. It raises questions about fairness and whether weight-loss treatment is only affordable for the wealthy.
Weight-loss medication is being called a tax on being thin. An analysis by consultancy Baringa says the high cost outweighs any saving on food for most people. Someone needs discretionary income of nearly Β£100,000 a year to actually save money. The annual cost of the medication averages Β£1,200. Baringa said GLP-1s risk becoming a driver of inequality. Only very high earners will benefit.
Nearly three million people in Britain are on weight-loss medication. Most buy the drugs privately with a prescription. A GLP-1 user with Β£39,000 left after tax and essentials spends Β£481 less a year on food. But people do not save the full Β£1,200 on groceries until they have Β£97,500 left after tax. A regressive tax takes a larger share from lower-wage earners. Baringa notes the outlay is an average for the pill form of the drug.
The cost of these drugs could widen the gap between rich and poor. It raises questions about fairness and whether weight-loss treatment is only affordable for the wealthy.